ReviewFrontiers in pharmacology2019
Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- Pristimerin Suppresses Janus Kinase/Signal Transducers and Activators of Transcription Oncogenic Signaling To Drive Mitochondrial and Caspase-Dependent Apoptosis in Multiple Myeloma.ACS pharmacology & translational science · 2026Article
- Diels-Alder Adducts fromInternational journal of molecular sciences · 2026Article
- Regulation of infant gut microbiota and metabolic pathways by human milk oligosaccharides: a multi-omics investigation.RSC advances · 2026Article
- Major bioactive metabolites derived fromFrontiers in pharmacology · 2026Review
- Development of 3D Cell-Based Fluorescent Reporter Assay for Screening of Drugs Downregulating Telomerase Reverse Transcriptase.Bioengineering (Basel, Switzerland) · 2025Article
- [Pristimerin enhances cisplatin-induced apoptosis in nasopharyngeal carcinoma cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Compound 225# inhibits the proliferation of human colorectal cancer cells by promoting cell cycle arrest and apoptosis induction.Oncology reports · 2024Article
- Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Comprehensive mass spectrometric metabolomic profiling of a chemically diverse collection of plants of the Celastraceae family.Scientific data · 2024Article
- Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD/ASC stability via selective autophagy to alleviate tendinopathy.Autophagy · 2024Article
- Maternal hyperglycemia inhibits pulmonary vasculogenesis during mouse fetal lung development by promoting GβL Ubiquitination-dependent mammalian target of Rapamycin assembly.Diabetology & metabolic syndrome · 2023Article
- Accurate delivery of pristimerin and paclitaxel by folic acid-linked nano-micelles for enhancing chemosensitivity in cancer therapy.Nano convergence · 2022Article
- Article
- Inhibition and potential treatment of colorectal cancer by natural compoundsFrontiers in oncology · 2022Review
- Antimalarial and antitumour activities of the steroidal quinone-methide celastrol and its combinations with artemiside, artemisone and methylene blue.Frontiers in pharmacology · 2022Article
- Bioactive small-molecule constituents of Lao plants.Journal of medicinal plant research · 2021Article
- One day at a time.Biomedical journal · 2021Article
- Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer.International journal of molecular sciences · 2021Review
- Review
- Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a quinonemethide triterpenoid extracted from species of the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.